While the overexpression of anti-cell death proteins, such as BAG3, and other pathways protective against cell damage confer cancer resistance, their contribution to the outcome of CD200-targeted therapies against breast cancer remains unclear [88]. The gene discussed is CD200; the disease is breast cancer.